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1. Introduction
Cancer biomarkers are biologic substances able to
measure molecular, cellular, tissue, or host factors as-
sociated with cancer susceptibility, pathogenesis, re-
sponse to treatment, or survival. Most familiar are
serum biomarkers associated with cancer progression
liketheclassictumormarkers,CEA,CA125,CA15.3,
or PSA. Their use has been extendedto early detection
as well as surrogate endpoints in prevention or treat-
ment trials. Many “classic” biomarkers are secreted
by cancer cells or are direct consequencesof the tumor
diathesis; and their levels closely correlate with tumor
burden. However, other biomarkers may not depend
upon a cancer being present. Rather, they may reﬂect
risk for or susceptibility to cancer.
There are several reasons why susceptibility or risk
biomarkers might represent an attractive strategy to re-
duce the morbidity and mortality of ovarian cancer.
Risk biomarkers might point to options for chemopre-
vention; e.g. raising levels of a nutrient that appears to
be deﬁcient. Even if the risk biomarker suggests no
obvious prevention strategy, women identiﬁed to be at
very high levels of risk for ovarian cancer could be of-
feredprophylacticsurgery. Primarypreventionofovar-
ian cancer through removal ovaries and tubes in high-
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risk women is already a reality through BRCA1 and
BRCA2 genetic testing, but such testing is costly and
may pertain to only 10% of women who may develop
ovarian cancer. Alternatively, risk biomarkers might
identify women who might be suitable for more inten-
sive screening. In this paper, we review non-genomic
risk biomarkers for ovarian cancer under the following
categories: micro and macronutrients, growth factors
and hormones, inﬂammatory markers, and mucins and
antibodies against them. We begin with a brief discus-
sion of methodologic aspects affecting the discovery
andapplicationofsusceptibilitybiomarkersforovarian
cancer.
2. Methodologic considerations
Several factors hamper the ease of investigating risk
biomarkersforovariancancer. Case-controlmethodol-
ogy that has been most commonly used to study ovar-
ian cancer has the obvious limitation that the cancer
cases are generally studied after diagnosis or therapy.
Thus,thecanceritselfmayaffectimmuneorinﬂamma-
torymarkers,whilesurgicalremovaloftheovarieswill
clearly alter levels of any hormonesrelated to the ovar-
ian/pituitary axis. Circulating nutrient levels are likely
to be altered by the disease itself, as tumorgrowth may
affect nutritional status, as well as by chemotherapy.
Thus, study of the level of a potential biomarker many
months (or years) prior to diagnosis is fundamental-
ly important. However, the relatively low incidence
of ovarian cancer (ovarian cancer is approximately 9
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timesless frequentthanbreastcancer)makestheuseof
prospective study designs particularly costly and inef-
ﬁcient. Despite this, several cohorts are large and now
mature enough so that a sufﬁcient number of ovarian
cancer cases have accumulated, making the study of
risk biomarkers possible.
Another important issue to be considered is whether
it is realistic to expect that a single measurement of a
biomarkercan capture the long-termbiologic milieu in
which a cancer may develop. Especially for a hormon-
al marker, variation by menopausal status, oral con-
traceptive or menopausal hormone use, phase of the
menstrual cycle, or even time of day may make data
from a single hormone measurement difﬁcult to inter-
pret. Williams and colleagues [1] showed that, aside
from estrone sulfate and sex hormonebinding globulin
(SHBG), for which a one-time measurement captured
most of the true variation in these hormone levels, a
single measurement of any particular gonadotropin or
sex steroid hormone is not representative of their long-
termlevels. Furtherdifﬁcultiesarise fromthe histolog-
ical diversity of ovarian cancer, where each type might
be associated with distinct risk factors or susceptibility
marker proﬁles. Finally, the etiology of ovarian cancer
is not yet completely understood; thus, we don’t have
a clear roadmap of the biologic processes that should
be targeted by potential risk biomarkers. Despite all
these difﬁculties, several risk biomarkershave been in-
vestigated in hope they could point to a strategy to de-
crease the morbidity and mortality of ovarian cancer
(summarized in Table 1).
3. Micro- and macronutrients
3.1. Anti-oxidants
Anti-oxidants are substances capable of reacting
with or neutralizing free radicals (reactive oxygen and
nitrogen species) that might otherwise cause genetic
damage and promote carcinogenesis [2]. A variety of
anti-oxidantmicronutrientshavebeenpostulatedtoex-
ert a protective effect on ovarian carcinogenesis, in-
cludingcarotenoids,alpha-tocopherolor vitaminE, vi-
tamin C, and selenium. Most of the studies have fo-
cused on estimating anti-oxidant intake using dietary
questionnaires. Case-controlstudiescomparingdietary
intake or supplementation between women diagnosed
with ovarian cancer (prior to disease) and cancer-free
women have suggested the following antioxidantsmay
reduce risk for ovarian cancer: vitamin E [3–6], vi-
tamin C [4], vitamin A [3,7,8], carotenoids [9], beta-
carotene [3,5,6,8,10–12], and lycopene [13]. Howev-
er, prospective epidemiologic studies based on dietary
intakefailedtoprovideevidencetosupportaroleofin-
creased intake of carotenoids [14–17], vitamin A [16],
vitamin C [15,16],or vitamin E [14,15]in ovariancan-
cer risk. A few prospective studies have evaluated
serum levels of micronutrientsas markers of risk. Hel-
zlsouer et al. [18] examined the association between
thelevelsofseveralmicronutrientsandsubsequentrisk
of ovarian cancer and found levels of carotenoids not
tobeassociatedwith ovariancancerrisk[18]. Forvita-
min E or alpha-tocopherol, these authors found higher
levels in women who developed ovarian cancer, sug-
gesting that greater alpha-tocopherol levels increased
subsequentrisk,whilenostatisticallysigniﬁcantdiffer-
ence was observed in alpha-tocopherol levels between
women who became cases and their matched controls
in a small study of ovarian cancer by Knekt et al. [19].
Selenium is another anti-oxidant that may be pro-
tective against cancers as suggested in several animal
models [20] and ecological data showing inverse cor-
relations between average selenium intake or selenium
bloodlevelsandcancermortality[21,22]. Thestudyof
selenium intake through dietary sources is not an op-
tion because selenium levels in foods vary substantial-
ly according to the selenium content in the soil. Thus
several epidemiologic studies have examined levels of
selenium in serum or in ﬁnger or toenails to assess se-
lenium intake in relation to cancer occurrence, includ-
ing two studies of ovarian cancer. While in one study
toenail selenium levels were not found to be associat-
ed with risk of developing ovarian cancer [23], Helzl-
souer et al reported greater than 70% reduction in risk
for those in the highest tertile of serum selenium lev-
els after excluding women who were diagnosed with-
in ovarian cancer 4 years after blood collection [18].
The discrepancy in ﬁndings is unlikely to be explained
by differences in the medium in which selenium was
measuredin thesetwo studiesas toenailseleniumseem
to be highly correlated with serum selenium measure-
ments (r =0 .89) [24]. Serum selenium was also not
associated with risk of gynecologic malignancies in a
study by Knekt et al. [25], but the number of ovarian
cancer cases was not stated in this study.
3.2. Vitamin D
Vitamin D and its metabolites have been implicat-
ed in reducing the risk of several cancers, includ-
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Table 1
Summary of studies examining non-genetic susceptibility biomarkers in ovarian carcinogenesis prospectively
Marker Study Design Participants Main Results Assays Reference
Micro and macro nutrients
Serum alpha-
tocopherol
Case-control nested
within cohort (Finland)
16 ovarian cancer cases
matched to 29 controls on
municipality and age
No association with ovari-
an cancer risk
Intra and inter-batch
CVs <10%
Knekt P.
1988 [19]
Serum α and γ-
tocopherol, α and
β-carotene, retinol,
cryptoxanthin,
lutein, lycopene,
selenium,
cholesterol
Case-control nested
within cohort (US)
35 ovarian cancer cases
matched to 67 controls on
race, age, menopause, fast-
ing, and timing of blood
collection
Elevated α-tocopherol and
cholesterol associated with
increased risk of ovarian
cancer (p-trend 0.04 and
0.02 respectively).
Selenium associated with
decrease in risk (p trend
0.02).
Ovarian cancer risk not
associated with γ-
tocopherol, α and β-
carotene, retinol, cryptox-
anthin, lutein, lycopene.
CVs: <10% for all
micro nutrients
studied except for α-
carotene (16.7%) and
cryptoxanthin
(10.8%).
Helzlsouer etal,
1996 [18]
Serum cholesterol Prospective cohort (US) 86,464 participants, 153
ovarian cancer cases
No association with ovari-
an cancer risk
CVs unavailable Hiatt and Fire-
man, 1986 [30]
Serum selenium Case-control nested
within cohort (Finland)
86 gynecologic cancers
matched to 172controls on
municipality and age.
No association with risk of
gynecologic cancers
Intra and inter-batch
CVs <10%
Knekt et al,
1990 [25]
Toe nail selenium Case-control study
nested within cohort
(US)
58 ovarian cancer cases
matched to 58 controls on
age and date of sample
collection.
No association with ovari-
an cancer risk
Garland et al,
1995 [23]
Hormonal biomarkers
Serum FSH, LH,an-
drostedione, DHEA
sulfate, estrone,
estradiol,
progesterone
Case-control study nest-
ed within cohort (US)
31 ovarian cancer cases
matched to 62 controls
on age, menopause status,
timing of blood collection
Lower FSH associated
with increased risk (p =
0.04)
Elevated androstedione as-
sociated with increased
risk (p trend 0.008)
Indication ofincreased risk
with elevated DHEA sul-
fate (p trend 0.11)
LH,estrone, estradiol, pro-
gesterone not association
with ovarian cancer risk
Intra and inter CVs
10%
Helzlsouer etal,
1995 [37]
Urinary DHEA, an-
drostedione, and
aetiocholanolone
Case-control study nest-
ed within cohort (Island
of Guernsey)
12 ovarian cancer cases
matched to 133controls on
age and menopause status.
Lower androgens associ-
ated with increased risk
(DHEA p =0 .007, an-
drostedione p =0 .06).
Aetiocholanone not asso-
ciated with ovarian cancer
risk
CVs unavailable Cuzick et al,
1983 [42]
Serum LH Case-control study
nested within cohort
(US)
58 ovarian cancer cases
matched to 116 controls
on age, menopause status,
timing of blood collection.
No association with ovari-
an cancer risk
Intra and inter CVs
<10%
Akhmedkhanov
et al, 2001 [36]
Serum FSH Pooled case-control
studies nested in 3
cohorts (US, Sweden,
Italy)
88 ovarian cancer cases
matched to 168 on age and
date of enrollment, cohort
(all postmenopausal)
No association with ovari-
an cancer risk.
Intra CVs <10%. Arslan et al,
2003 [76]
Serum testosterone,
androstedione,
DHEAS, SHBG,
estrone
Pooled case-control
studies nested in 3
cohorts (US, Sweden,
Italy)
132 ovarian cancer cas-
es matched to 168 on
age, date of enrollment,
menopause status, cohort)
Elevated androstedione in-
creased
ovarian cancer risk among
pre-menopausal women (p
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Table 1, continued
Marker Study Design Participants Main Results Assays Reference
Testosterone, DHEAS,
SHBG, estrone not asso-
ciated with ovarian cancer
risk.
IntraCVs<10%, inter
CVs  15.1%
Lukanova et al,
2003 [39]
Serum IGF-1 and
IGFBP-3
Pooled case-control
studies nested in 3
cohorts (US, Sweden,
Italy)
132 ovarian cancer cas-
es matched to 168 con-
trols on age, date of en-
rollment, menopause sta-
tus, and cohort.
Increased IGF-1 levels as-
sociated with increased
risk among women <55 (p
trend <0.03).
IGBPB-3 not associated
with ovarian cancer risk.
Intra and inter batch
CVs <10%.
Lukanova et al,
2002 [51]
Serum IgF-1 and
IGFBP-3
Pooled case-control
studies nested in EPIC
cohort (Denmark,
France, Germany,
Greence, Italy, The
Netherlands, Spain,
The United Kingdom)
214 cases matched to 388
controls on study cen-
ter, menopause status, age,
time of blood collection,
fasting status, and phase
of menstrual cycle (in pre-
menopausal participants)
Elevated IGF-1 associated
with increased risk among
women <55 years at di-
agnosis (p-trend 0.08) and
among women who were
pre-menopausal at blood
collectionand<55yearsat
diagnosis (p-trend 0.02)
Elevated
IGFBP-3 non-signiﬁcantly
associated with increased
risk among women <55
years at diagnosis
Mean intrabatch
CVs < 4%; mean
inter-batch CVs
< 13%
Peeters et al.
2007 [52]
Plasma IGF-1,
IGFBP-2, IGFBP-3
Pooled nested case-
control studies from
3 cohorts (US)
222 ovarian cancer cases
matched to 599controls on
menopause status, andage,
fasting status andPMHuse
at blood collection.
Suggestive of inverse as-
sociation between elevated
IGF-1 and cancer risk (p-
trend 0.14).
No signiﬁcant associa-
tion between IGFBP-2 or
IGFBP-3 and cancer risk
Intra-assay CVs
10%
Tworoger et al.
2007 [53]
Serum c-peptide,
IGFBP-1, IGFBP-2
Pooled case-control
studies nested in 3
cohorts (US, Sweden,
Italy)
132 ovarian cancer cas-
es matched to 168 con-
trols on age, date of en-
rollment, menopause sta-
tus, and cohort.
Elevated IGFBP-1 and
IGFBP-2 associated with
non-signiﬁcant decrease in
risk (among women <55
years)
C-peptide not associated
with ovarian cancer risk.
Intra and inter CVs
11 and 16.2%
Lukanova et al,
2003 [47]
Inﬂammatory markers
Serum soluble Fas Pooled case-control
studies nested in 3
cohorts (US, Sweden,
Italy)
138 ovarian cancer cas-
es matched to 263 con-
trols on age, date of en-
rollment, menopause sta-
tus, and cohort.
No association with ovari-
an cancer risk
Intra and inter CVs
<10%
Akhmedkhanov
et al, 2003 [59]
Mucins
Serum CA 125 Case-control nested
within cohort (JANUS
serum bank, Norway)
105 ovarian cancer cases
matched to 323 controls
on age, residence, time of
samplecollection andsam-
ple storage conditions.
Levels of CA 125 lower
among controls than cases
diagnosed up to 12 years
(p<0.001)
Inter assay CVs
<15%
Zurawski et al,
1988 [31]
Serum CA 125 Case-control study nest-
ed within cohort (US)
37 ovarian cancer cases
matched to 73 controls on
age and time since last
menstrual period.
Levels of CA 125 lower
among controls than cases
diagnosed up to 12 years
after blood collection (p =
0.002).
Intra batch CVs
ranged from 6 to 16%
depending on CA 125
concentrations
Helzlsouer etal,
1993 [65]
Serum CA 125 Prospective cohort (In-
terventional screening
study)
22,000 post-menopausal-
women, 49 ovarian or
epithelial cancer cases
CA 125 levels >30 U/ml
associated with increased
risk of ovarian cancer (OR
and 95% CI within ﬁve
years after screen: 14.3
(8.5, 24.3)
Intra and inter CVs
<10%
Jacobs et al,
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ed mechanisms explaining the potential protective ef-
fects of vitamin D include inhibition of angiogenesis
and enhancement of cell adherence, which in turn in-
hibit cell proliferation and may protect against tumori-
genesis. Several ecologic studies have reported that
ovarian cancer mortality is higher in areas of lower
sunlight or lower dietary vitamin D intake (reviewed
in [26]). A group of investigators have recently exam-
ined the relation between serum vitamin D metabolites
(25-hydroxyvitamin D and 1,25-dihydroxyvitamin D)
and risk of developingovarian cancer in a case-control
study nested within the Nurses Health Study. Over-
all, circulating levels of vitamin D metabolites did not
seem to be associated with subsequent risk of devel-
oping ovarian cancer, although a protective effect of
25-hydroxyvitaminD was suggested among obese and
overweightwomen(p =0 .04)[27],which will needto
be replicated in further prospective studies.
3.3. Cholesterol
Therehasbeensomeepidemiologicevidencetosug-
gest that dietary fats, including cholesterol, may in-
crease risk of certain cancers including ovarian malig-
nancies[10,28]. Onebiologicrationaleforthepotential
inﬂuence of high cholesterol in ovarian carcinogenesis
is that cholesterol is a steroid precursor that could lead
to increased biosynthesis of estrogens, which may in-
creaseovariancancerrisk. However,ina recentpooled
analysis of 12 cohort studies of dietary fats, Genkinger
et al. [29] found no evidence for a role of dietary fat or
cholesterol in ovarian cancer risk. Thus, it is not sur-
prising that the association between serum cholesterol
levels and subsequent risk of ovarian cancer, explored
todateinonlytwoprospectivestudies,producedincon-
clusive ﬁndings. Helzlsouer et al. [18] reporteda high-
er than 3-fold increase in ovarian cancer risk among
womeninthe highesttertile ofserumcholesterollevels
comparedtothoseinthelowesttertile. Afterexcluding
women diagnosed within 4 years of blood collection,
the ORs forthosein the highesttertile remainedelevat-
ed, though no longer statistically signiﬁcantly elevated
(OR and 95% CI: 2.9 (0.7, 11.3)). In contrast to the
ﬁndings reported by Helzlsouer et al,cholesterol levels
were not found to be associated with ovarian cancer
incidence in a large cohort where 190 women devel-
oped ovarian cancer over the course of up to 16 years
of follow-up [30].
4. Hormonal biomarkers
4.1. Gonadotropins
It has been postulated that excessive stimulation of
theovariesbypituitarygonadotropinsmayincreaserisk
of malignant transformationboth directly and indirect-
ly through stimulation of sex steroid production [31].
Animal models using ovarian irradiation or chemicals
toxic to oocytes raised gonadotropin levels and pro-
duced ovarian tumors, albeit not entirely comparable
to the epithelial tumors in women [32,33]. Results of
epidemiologic studies compatible with an effect of go-
nadotropininclude ovarian cancers observed after irra-
diation for cervical cancer [34] or protection associat-
ed with birth control pill use, which profoundly lower
gonadotropins [35]. The association between prediag-
nostic levels of gonadotropins and ovarian cancer has
been examined in only two studies. In one study, no
association was found [36], and in the other an inverse
association was observed. In this study, Helzlsouer et
al. [37] reported lower gonadotropinlevels (particular-
lyfollicle-stimulatinghormone)inwomensubsequent-
ly diagnosed with ovarian cancer compared to con-
trols,particularlyamongpost-menopausalwomen. Al-
though relatively small and based on a single measure-
ment of gonadotropin levels, these studies fail to pro-
vide support for a role of circulating gonadotropins as
markers of increased susceptibility to the development
of ovarian cancer.
4.2. Estrogens and progesterone
Estrogen and progesterone production in the pre-
menopausal woman occurs almost entirely in the
ovaries where the synthesis of sex-steroid hormones is
under the control of gonadotropins acting on the gran-
ulosa and theca cells of the developing follicle. Ovar-
ian epithelial tumors, which have the appearance of
estrogen-sensitive Mullierian tissues, may contain es-
trogen and progesterone receptors [38]. To date, only
two studies have directly investigated the relation be-
tween circulating levels of estrogens and subsequent
risk of ovarian cancer [37,39]. Both studies were null,
providingno support for a major role of circulating es-
trogensonovariancarcinogenesis. Lukanovaetal.[39]
also investigated the role of sex hormone-bindingpro-
tein (SHBG), which is the major binding globulin of
estradiol and determines the levels of biologically ac-
tive estradiol. They found no inﬂuence of SHBG on
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ments of estrone and SHBG were obtained 11 to 60
months apart, and intra-class correlations of 0.89 for
estrone (among post-menopausal women only) and of
0.89 for SHBG were reported.
Contrary to the presumed harmful effects of estro-
gen,progesteroneexcesshasbeenpostulatedtobeben-
eﬁcial [40]. After the second month of pregnancy, the
placental synthesis of progesterone is responsible for
a close to 10-fold increase in the maternal circulating
levels of progesterone, which led some to hypothesize
that progesterone could account at least in part for the
protective effects of pregnancy on ovarian cancer risk.
However, the only study conducted to date to directly
examinetheassociationbetweenlevelsofprogesterone
and subsequent risk of ovarian cancer found no con-
vincing evidence for a role of progesterone on ovarian
carcinogenesis [37].
4.3. Androgens
Androgenshavealsobeenproposedtoincreaseovar-
ian cancer risk according to several lines of evidence
reviewed by Risch [40]. Ovarian epithelial cells con-
tainandrogenreceptors,andovarianepithelialcelllines
treated with androgens have shown increased prolifer-
ation rate and decreased rate of cell death [41]. Epi-
demiologic evidence supporting the androgen hypoth-
esis includethe protectionconferredbyoral contracep-
tive use, which reduce circulating levels of androgen
andthe increasedrisk observedwith womendiagnosed
with Polycystic Ovarian Syndrome(PCOS), character-
ized by elevated circulating androgen levels.
More direct evidence for a role of androgens in
the development of ovarian cancer was provided by 2
prospective studies [37,39], both of which showed an
increasedovariancancerrisk (thoughnon-signiﬁcantly
in one [39]) among those with elevated prediagnostic
serum levels of androstenedione (particularly among
pre-menopausal women). Interestingly, urinary andro-
gens levels were shown to be lower in controls com-
paredtocasesinanearliersmallprospectivestudycon-
ducted in the Island of Guernsey [42]. However, the
small size of this study (12 cases) increases the proba-
bility that chance played a role in their ﬁndings. Alter-
natively,itispossiblethathigherurinaryconcentrations
of androgens do not correspond to elevated circulating
levels of androgens.
4.4. Insulin
Insulin has both mitogenic and anti-apoptotic prop-
erties and has been implicated in several cancers, in-
cluding colon, breast, and pancreatic cancer [43]. In-
sulin may inﬂuence ovarian cancer risk on one hand
by stimulating LH-induced androgen production, and
on the other hand by downregulating the expression of
sexhormonebindingglobulin(SHBG) andinsulin-like
growth (IGF) factor binding protein 1, thereby inﬂu-
encinglevelsof biologicallyactive, freecirculatingsex
steroids hormones and IGF-I [40,44]. Despite an ap-
pealingbiologicrationale, epidemiologicdata have not
provided clear support for a role for insulin in ovarian
carcinogenesis. Conditions intimately associated with
increasedinsulinproductionsuchasobesityandtypeII
diabetes mellitus have been shown to exert minimal or
no effect on ovarian cancer risk, respectively [45,46].
The only prospective study examining the association
between circulating c-peptide levels, a marker of pan-
creatic insulin secretion, also failed to provide support
for a role of insulin in ovarian cancer [47].
4.5. Insulin-Like Growth Factor and its binding
protein
Themitogenicandanti-apoptoticpropertiesofIGF-I
arewelldocumented. ElevatedconcentrationsofIGF-I
are believed to play a role in the etiology of several
types of cancers, includingpre-menopausalbreast, and
prostate, lung, and colorectal cancers [48,49]. IGF-I
anditsbindingproteinsarethoughttoinﬂuencethereg-
ulation of ovarian follicular development and to have
mitogenic and anti-apoptoticeffects on ovarian epithe-
lial cells [50]. Three prospective studies have exam-
inedtheroleofelevatedIGF-Ilevelsinovariancarcino-
genesis. In two studies, higher circulating IGF-I levels
were associated with 2.4 to 4.7 fold increase in risk of
ovarian cancer among women diagnosed at relatively
youngages [52]. This increase in risk was accentuated
amongwomen who were pre-menopausalat bloodcol-
lection (higher tertile associated with 5.6 fold increase
in risk)[52]. Paradoxically,elevatedIGF-1 levelswere
suggestive of a decrease in ovarian cancer risk in a re-
cent pooled nested case-controlstudy (p-trendnon sig-
niﬁcant);theirresultsdidnotappeartodifferaccording
to age at diagnosis or menopausal status [53]. Several
IGF binding proteins are known to exist and function
to reduce both availability of IGF-I and its biologic ac-
tivity. Increasing levels of IGF binding proteins 1 and
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fect on subsequent ovarian cancer risk among women
diagnosed before the age of 55 in a study by Lukanova
et al. [49]. Although no clear relation between IGF
binding protein 3 was observed in most prospective
studies, Peeters et al. [52] suggested a non-signiﬁcant
increase in risk with increasing concentrations among
women diagnosed before the age of 55 years.
5. Inﬂammatory biomarkers
To address some of the shortcomings of earlier epi-
demiologic models for ovarian cancer based on inces-
sant ovulation or gonadotropin excess, Ness and Cot-
treau [54] offered their theory that inﬂammation might
explain the role of a number of risk factors for ovari-
an cancer including talc use, endometriosis, and ovu-
lation. The process of inﬂammation involves the pro-
duction of free radicals and recruitment of inﬂamma-
tory mediators such as cytokines and prostaglandins,
which can be mutagenic and contribute to the develop-
ment of cancer including ovarian. Several inﬂammato-
ry mediators have been found to be elevated in ovarian
cancer tumors and some were associated with disease
progression. Cytokines including TNF-α, IL-6, IL-1α
and IL-1γ were found to be elevated in ovarian tumors
and in women with ovarian tumors. Levels of TNF-
α were found to be indicative of ovarian tumor grade
while levels of several inﬂammatory markers such as
IL-6, IL-8, and VEGF were found to be indicative of
early stage ovarian tumors [55–58].
Because presence of tumor is likely to induce in-
ﬂammatory responses, it is important that studies ex-
amine the role of inﬂammatory biomarkers measured
(preferably) several years before diagnosis. Akhmed-
khanov et al. [59] examined the association between
levels of soluble Fas and the risk of developingovarian
cancer in a case-control study nested within 3 cohort
studies. Soluble Fas is a member of the tumor necrosis
factor receptor family, is one of the major regulators
of cellular apoptosis in many physiologic processes,
and dysregulation of Fas-mediated apoptosis has been
postulated to play a role in ovarian tumorigenesis [60].
Despite the strong biologic rational, Akhmedhanov et
al. [59] found that serum soluble Fas did not differ be-
tween cases and controls failing to show that soluble
Fas would be a useful susceptibility marker in ovarian
carcinogenesis.
6. Mucins and antibodies against them
6.1. Epithelial mucins
The epithelial mucins are soluble or membrane-
bound glycoproteins that are products of the human
mucin family of genes. The ﬁrst mucin to be described
was MUC1, also known as CA 15.3. MUC 1 is an es-
pecially ubiquitous glycoprotein that occurs along the
apicalborderofepithelialcellsliningthegenital,respi-
ratory, and digestive tracts and breast ducts. With can-
cer, mucins become over-expressed and are released
into the circulation and have thus become valuable tu-
mor markers. MUC 1 has been proposed as a potential
marker of for breast, pancreatic, endometrial, colon,
and lung cancer. For ovarian cancer the best known
mucin marker is MUC16, originally called CA 125.
However,othermucinshavealsobeenstudiedaspoten-
tialmarkersofovariancarcinogenesis. MucinsMUC1,
MUC2, MUC4, and MUC5AC were found to be ex-
pressed in epithelial ovarian cancer cells; MUC3 and
MUC4wereassociatedwithtumorstageandprolonged
survival [61].
One of the most widely studied mucins, MUC16, or
CA 125, has been approved as a marker for the moni-
toringofovariancancer,buthasalso beenusedas a po-
tential marker for early detection. Several studies have
found CA 125 to be elevated shortly prior to diagnosis
of ovarian cancer [62–64]. More intriguing, however,
are studies that suggest CA 125 may be elevated many
years prior to cancer. In a nested case-control study,
Zurawski et al. [31] showed that prediagnostic CA 125
levels as low as 10 U/ml were associated with a close
to 4-fold increase in risk of developing ovarian cancer
over 12 years of follow-up. In this study, median CA
125levelswereconsistentlyhigheramongwomenwho
subsequently developed ovarian cancer 2, 3, or 5 years
after blood collection, compared to controls. Helzl-
souer et al. [65] also observed higher median CA 125
levels in cases compared to controls within 12 years of
followup,althoughthisﬁndingwasonlysigniﬁcantfor
thecasesdiagnosedwithintheﬁrst3yearsofbloodcol-
lection. Inthissmallnestedcase-controlstudy,CA125
levels as low as 10 U/ml were associated with a greater
than 5-fold increase in risk of developing ovarian can-
cer over 12 years of follow-up. In a more recent inter-
ventional screening study of post-menopausal women,
Jacobsandcolleagues[66]reportedthatelevatedblood
levels of CA 125 (30 U/ml) were associated with a
14-fold increase risk of developing ovarian or fallop-
ian tube cancers within the ﬁrst 5 years of CA blood362 S.P. Pinheiro and D.W. Cramer / Non-genomic biomarkers of risk in ovarian cancer
Fig. 1. Likelihood of testing positive for anti-MUC1 antibodies and risk of ovarian cancer as function of the number of protective events over a
woman’s lifetime (reprinted from Cramer et al. [71]).
measurements. Clearlythereremainssomeuncertainty
in these studies whether CA 125 is serving as an ear-
ly detection or a risk biomarker, as some women who
developedovariancancer shortlyafter blood collection
were includedin these analyses. However,the fact that
CA 125 levels were noted to be higher in women who
developedovarian cancer 4 to 12 years after blood col-
lection compared to those who remained cancer-free,
suggestsa roleforCA 125as a markerofsusceptibility
for ovarian cancer [65] in addition to its more recog-
nizedroleasarecurrencebiomarker. Furtherandlarger
prospectivestudies in which blood levels are measured
a decade or more before the developmentof the cancer
may be necessary to help us better deﬁne the role of
CA 125 levels in ovarian cancer susceptibility.
6.2. Anti-MUC1 antibodies
An epidemiologic basis for proposing immunity as
a basis for interpreting cancer risk probably dates back
to 1980 with the “fetal antigen” theory for breast can-
cer[67]. Thistheoryproposedthat,duringapregnancy,
women are exposed to fetal antigens that may be simi-
lar to antigens expressed by breast tumors and form an
immunityto them that may account, at least in part, for
the long-term protective effect of pregnancy on breast
cancer risk. Later it was proposed that the cell surface
glycoproteinandhumanmucin(MUC)familymember,
MUC1, might be the hypothetical immunity-inducing
antigen since it is both secreted during pregnancy and
overexpressedin breastcancer[68]. It has beenshown
that sera from multiparous women – but not from nul-
liparous women or from men – are able to mediate
killing of breast cancer cells. Supporting a key role for
MUC1 in these reactions, core-peptidesequences from
MUC1caninduceproliferationofTcellsandcytotoxic
T cell responses in multiparous women [69]. The “fe-
tal antigen” hypothesis was extendedto ovarian cancer
after it was shown that sera from multiparous women
alsoreactedwithmultipleantigensfromovariancancer
cells more strongly than sera from nulliparous wom-
en or men [70], although MUC1 was not speciﬁcally
examined in these experiments.
Because it is known that many cancers, includ-
ing ovarian, over-express epithelial mucin, MUC1,
and promote anti-MUC1 antibodies that correlate with
morefavorableprognosis,itwasrecentlyproposedthat
riskforovariancancermightbereducedbypre-existing
MUC-1 speciﬁc immunity [71]. In this paper, anti-
MUC1 antibodies were measured in 705 control wom-
en, and events were identiﬁed that predicted antibod-
ies. Ovarian cancer risk was then estimated by com-
paring proﬁles of events generating antibodies in con-
trols with those in 668 ovarian cancer cases. Factors
predicting antibodies included oral contraceptive use,
breast mastitis, bone fracture or osteoporosis, pelvic
surgeries, non-use of talc in genital hygiene, and to a
lesser extent intrauterine device use and current smok-
ing. There was a signiﬁcant increase in the likelihood
ofhavinganti-MUC1antibodiesfrom24.2%inwomen
with 0 or 1 condition, to 51.4% in those with 5 or more
conditions. By the same index of events, the risk for
ovarian cancer was inversely associated with number
of conditions predisposing to anti-MUC1 antibodies.
Compared to having experienced 0 or 1 event, the ad-
justed risk for ovarian cancer decreased progressive-
ly with RRs (and 95% CI) of 0.69 (0.52, 0,92), 0.64
(0.47, 0.88), 0.49 (0.34, 0.72), and 0.31 (0.16, 0.61),
respectively for women with 2, 3, 4, and 5 or more
events related to the presence of antibodies (p for trendS.P. Pinheiro and D.W. Cramer / Non-genomic biomarkers of risk in ovarian cancer 363
< 0.0001) (Fig. 1). The authors concluded that several
traditional and new risk factors for ovarian cancer may
beexplainedbytheirabilitytoinduceMUC1immunity
through exposure of MUC1 to immune recognition in
the context of inﬂammatory or hormonal processes in
various MUC1-positive tissues.
Although intriguing, it should be appreciated that
the role of anti-MUC1 antibodies as risk biomarkers
was not directly assessed in this case-control study but
rather only inferred by comparing the frequency of
eventspredictingantibodiesincasesandcontrols. Thus
the value of anti-MUC1 antibodies as a risk biomarker
still needs to be assessed in pre-diagnostic sera. In ad-
dition, other immune antibodies to ovariancancer anti-
gens might also be useful as risk biomarkersincluding,
for example, antibodies against MUC16.
7. Discussion
During the last decade, there has been an increased
interest in the use of biomarkers in cancer research
to identify early disease and better understand the ac-
quired and inherited susceptibility to the development
ofcancer. Ourreviewhasfocusedonnon-genomicrisk
biomarkers including nutrients, hormones, and inﬂam-
matory or immune factors. Despite a large number of
case-control studies based on dietary estimates of nu-
trient intake, prospective studies of serum nutrient lev-
els have not generally shown a good correlation with
ovariancancerrisk. Amongthemicronutrientsstudied,
it is possiblethat elevatedselenium levels mayindicate
lower ovarian cancer risk and elevated vitamin E and
cholesterol levels may indicate some increase in risk.
However, inconsistencies in the studies and uncertain
biologicalmechanisms connectingnutrients with ovar-
iancarcinogenesissuggesttheneedforfurtherprospec-
tive studies before a deﬁnitive chemopreventive plan
involving nutrients is suggested, even though this may
have popular appeal.
Regarding hormonal biomarkers of risk for ovari-
an cancer, we found little evidence to support a ma-
jor role for estrogens, progesterone, SHBG, and in-
sulin, in ovarian carcinogenesis. On the other hand,
there is some evidence suggesting that increased cir-
culating levels of IGF-I and androgens may indicate
an increased risk of ovarian tumors, especially among
pre-menopausal women. Although it is not yet certain
how the latter two hormones might operate to increase
ovarian cancer risk, it has been observed that andro-
gensmaysynergizewithIGF-Itoincreaseproliferation
of cancer cell lines [72,73]. From a chemoprevention
standpointthe observationregardingIGF-I and Andro-
gens are important since oral contraceptives are able
to signiﬁcantly lower both androgens and IGF-I [74,
75]. This provides an additional rationale for use of
oralcontraceptivestolowerovariancancerriskinaddi-
tion to its ability to reduce the damage from “incessant
ovulation.”
It is now generally accepted that inﬂammato-
ry/immune factors may play important role in carcino-
genesis including that related to the ovary. Although
larger prospective studies that exclude women diag-
nosed within a couple of years of blood collection will
be needed before deﬁnitive conclusions can be drawn,
antibodies against MUC1 may prove to be a promising
marker indicative of ovarian cancer risk. A better un-
derstanding of the role of MUC1 antibodies in ovarian
carcinogenesis will provide greater insight into the eti-
ology of this malignancy and may point towards nov-
el treatment and prevention strategies against ovarian
cancer.
In conclusion, at the present time, there does not
seem to be enough evidence to suggest any biomark-
er with a strong enough impact on ovarian cancer
riskto justify recommendationsofpreventiveinterven-
tions such as the removal of ovaries or fallopian tubes.
Rather, this review points to a few markers that may
have important implications in chemoprevention or in
the targeting women for more intensive screening.
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